CSL faces EU revocation of TAVNEOS authorisation, $145m in FY26 sales at risk
CSL Limited (ASX:CSL) has reported that the European Medicines Agency’s CHMP has issued an opinion recommending the revocation of the EU marketing authorisation for TAVNEOS (avacopan), an in‑licensed therapy sold in EU and EEA markets by CSL Vifor affiliates.










